The ongoing challenge of latent tuberculosis

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1645, 2014, Pages

  Esmail, H ^a,b   Barry III, C E ^c   Young, D B ^a,d   Wilkinson, R J ^a,b,d  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF CAPE TOWN   (South Africa)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^d NATIONAL INSTITUTE FOR MEDICAL RESEARCH   (United Kingdom)

Author keywords

Diagnosis; Elimination; Latent tuberculosis; Mycobacterium tuberculosis; Natural history; Treatment

Indexed keywords

DISEASE; DISEASE INCIDENCE; DRUG; HEALTH RISK; INNOVATION; PUBLIC HEALTH; TUBERCULOSIS;

EID: 84900317225     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0437     Document Type: Review

References (129)

1. Gagneux S. 2012 Host-pathogen coevolution in human tuberculosis. Phil. Trans. R. Soc. B 367, 850-859. (doi:10.1098/rstb.2011.0316)
2. Comas I et al. 2013 Out-of-Africa migration and Neolithic coexpansion of Mycobacterium tuberculosis with modern humans. Nat. Genet. 45, 1176-1182. (doi:10.1038/ng.2744)
3. Wirth T et al. 2008 Origin, spread and demography of the Mycobacterium tuberculosis complex. PLoS Pathog. 4, e1000160. (doi:10.1371/journal.ppat. 1000160)
4. Blaser MJ, Kirschner D. 2007 The equilibria that allow bacterial persistence in human hosts. Nature 449, 843-849. (doi:10.1038/nature06198)
5. Hershberg R et al. 2008 High functional diversity in Mycobacterium tuberculosis driven by genetic drift and human demography. PLoS Biol. 6, e311. (doi:10.1371/journal.pbio.0060311)
6. de Jong BC et al. 2008 Progression to active tuberculosis, but not transmission, varies by Mycobacterium tuberculosis lineage in The Gambia. J. Infect. Dis. 198, 1037-1043. (doi:10.1086/ 591504)
7. WHO. 2011 Global tuberculosis control 2011. Geneva, Switzerland: World Health Organization.
8. WHO. 2006 The global plan to stop TB 2006-2015: Stop TB partnership. Geneva, Switzerland: World Health Organization.
9. WHO. 2013 Global tuberculosis report 2013. Geneva, Switzerland: World Health Organization.
10. Dye C, Glaziou P, Floyd K, Raviglione M. 2013 Prospects for tuberculosis elimination. Annu. Rev. Public Health 34, 271-286. (doi:10.1146/annurevpublhealth-031912-114431)
11. Dye C, Hosseini M, Watt C. 2007 Did we reach the 2005 targets for tuberculosis control? Bull. World Health Organ. 85, 364-369. (doi:10.2471/BLT.06. 037580)
12. WHO. 2013 Countdown to 2015: global tuberculosis report 2013 supplement. Geneva, Switzerland: World Health Organization.
13. Abu-Raddad LJ, Sabatelli L, Achterberg JT, Sugimoto JD, Longini Jr IM, Dye C, Halloran ME. 2009 Epidemiological benefits of more-effective tuberculosis vaccines, drugs, and diagnostics. Proc. Natl Acad. Sci. USA 106, 13 980-13 985. (doi:10. 1073/pnas.0901720106)
14. Opie EL, McPhedran FM. 1926 The contagion of tuberculosis. Am. Rev. Tuberc. 14, 347-385.
15. Yik Wang C. 1916 An experimental study of latent tuberculosis. Lancet 188, 417-419. (doi:10.1016/ S0140-6736(00)58936-3)
16. Newsholme A. 1908 The history of phthisis. In The prevention of tuberculosis, 2nd edn, pp. 35-42. London, UK: Methuen and Co.
17. Koch R. 1890 A further communication on a remedy for tuberculosis. Br. Med. J. 2, 1193-1199. (doi:10. 1136/bmj.2.1560.1193)
18. Rieder HL. 1999 Epidemiologic basis of tuberculosis control. Paris, France: International Union Against Tuberculosis and Lung Disease.
19. Mills CC, O'Grady F, Riley RL. 1960 Tuberculin conversion in the 'naturally infected' guinea pig. Bull. Johns Hopkins Hosp. 106, 36-45.
20. Dharmadhikari AS et al. 2011 Natural infection of guinea pigs exposed to patients with highly drugresistant tuberculosis. Tuberculosis 91, 329-338. (doi:10.1016/j.tube.2011.03.002)
21. Escombe AR et al. 2007 The detection of airborne transmission of tuberculosis from HIV-infected patients, using an in vivo air sampling model. Clin. Infect. Dis. 44, 1349-1357. (doi:10.1086/515397)
22. Ferebee SH. 1970 Controlled chemoprophylaxis trials in tuberculosis: a general review. Bibl. Tuberc. 26, 28-106.
23. Diel R, Loddenkemper R, Nienhaus A. 2012 Predictive value of interferon-gamma release assays and tuberculin skin testing for progression from latent TB infection to disease state: a meta-analysis. Chest 142, 63-75. (doi:10.1378/chest.11-3157)
24. Rangaka MX, Wilkinson KA, Glynn JR, Ling D, Menzies D, Mwansa-Kambafwile J, Fielding K, Wilkinson RJ, Pai M. 2011 Predictive value of interferon-gamma release assays for incident active tuberculosis: a systematic review and meta-analysis. Lancet Infect. Dis. 12, 45-55. (doi:10.1016/S1473-3099(11)70210-9)
25. Smieja MJ, Marchetti CA, Cook DJ, Smaill FM. 2000 Isoniazid for preventing tuberculosis in non-HIV infected persons. Cochrane Database Syst. Rev. 2000, CD001363. (doi:10.1002/14651858. CD001363)
26. Dye C, Scheele S, Dolin P, Pathania V, Raviglione MC. 1999 Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO global surveillance and monitoring project. JAMA 282, 677-686. (doi:10. 1001/jama.282.7.677)
27. Dye C, Bassili A et al. 2008 Measuring tuberculosis burden, trends, and the impact of control programmes. Lancet Infect. Dis. 8, 233-243. (doi:10.1016/S1473-3099(07)70291-8)
28. Styblo K. 1985 The relationship between the risk of tuberculous infection and the risk of developing infectious tuberculosis. Bull. Int. Union Tuberc. 60, 117-119.
29. Rieder HL, Chadha VK, Nagelkerke NJ, van Leth F, van der Werf MJ. 2011 Guidelines for conducting tuberculin skin test surveys in high-prevalence countries. Int. J. Tuberc. Lung Dis. 15(Suppl. 1), S1-S25.
30. Rieder HL. 1995 Methodological issues in the estimation of the tuberculosis problem from tuberculin surveys. Tuberc. Lung Dis. 76, 114-121. (doi:10.1016/0962-8479(95)90552-9)
31. Pai M, Dendukuri N, Wang L, Joshi R, Kalantri S, Rieder HL. 2008 Improving the estimation of tuberculosis infection prevalence using T-cell-based assay and mixture models. Int. J. Tuberc. Lung Dis. 12, 895-902.
32. Aggerbeck H, Giemza R, Joshi P, Tingskov PN, Hoff ST, Boyle J, Andersen P, Lewis DJ. 2013 Randomised clinical trial investigating the specificity of a novel skin test (C-Tb) for diagnosis of M. tuberculosis infection. PLoS ONE 8, e64215. (doi:10.1371/journal. pone.0064215)
33. Dye C. 2008 Breaking a law: tuberculosis disobeys Styblo's rule. Bull. World Health Organ. 86, 4. (doi:10.2471/BLT.07.049510)
34. van Leth F, van der Werf MJ, Borgdorff MW. 2008 Prevalence of tuberculous infection and incidence of tuberculosis: a re-assessment of the Styblo rule. Bull. World Health Organ. 86, 20-26. (doi:10.2471/ BLT.06.037804)
35. Jones-Lopez EC et al. 2013 Cough aerosols of Mycobacterium tuberculosis predict new infection: a household contact study. Am. J. Respir. Crit. Care Med. 187, 1007-1015. (doi:10.1164/rccm.201208-1422OC)
36. Escombe AR et al. 2008 The infectiousness of tuberculosis patients coinfected with HIV. PLoS Med. 5, e188. (doi:10.1371/journal.pmed.0050188)
37. Gagneux S. 2013 Genetic diversity in Mycobacterium tuberculosis. Curr. Top. Microbiol. Immunol. 374, 1-25. (doi:10.1007/82_2013_329)
38. Portevin D, Gagneux S, Comas I, Young D. 2011 Human macrophage responses to clinical isolates from the Mycobacterium tuberculosis complex discriminate between ancient and modern lineages. PLoS Pathog. 7, e1001307. (doi:10.1371/journal. ppat.1001307)
39. Yang C, Luo T, Sun G, Qiao K, DeRiemer K, Mei J, Gao Q. 2012 Mycobacterium tuberculosis Beijing strains favor transmission but not drug resistance in China. Clin. Infect. Dis. 55, 1179-1187. (doi:10. 1093/cid/cis670)
40. Via LE et al. 2013 Differential virulence and disease progression following Mycobacterium tuberculosis complex infection of the common marmoset (Callithrix jacchus). Infect. Immun. 81, 2909-2919. (doi:10.1128/IAI.00632-13)
41. Dowdy DW, Dye C, Cohen T. 2013 Data needs for evidence-based decisions: a tuberculosis modeler's 'wish list'. Int. J. Tuberc. Lung Dis. 17, 866-877. (doi:10.5588/ijtld.12.0573)
42. Comas I, Chakravartti J, Small PM, Galagan J, Niemann S, Kremer K, Ernst JD, Gagneux S. 2010 Human T cell epitopes of Mycobacterium tuberculosis are evolutionarily hyperconserved. Nat. Genet. 42, 498-503. (doi:10.1038/ng.590)
43. Wells WF. 1955 Airbourne contagion and air hygiene: an ecological study of droplet infections, 1st edn. Boston, MA: Harvard University Press.
44. Fox GJ, Barry SE, Britton WJ, Marks GB. 2012 Contact investigation for tuberculosis: a systematic review and meta-analysis. Eur. Respir. J. 41, 140-156. (doi:10.1183/09031936.00070812)
45. Medlar EM. 1948 The pathogenesis of minimal pulmonary tuberculosis; a study of 1,225 necropsies in cases of sudden and unexpected death. Am. Rev. Tuberc. 58, 583-611.
46. Canetti G. 1955 Histology of pulmonary tuberculosis: a review. In The tubercle bacillus in the pulmonary lesion of man; histobacteriology and its bearing on the therapy of pulmonary tuberculosis, 1st edn, pp. 7-28. New York, NY: Springer.
47. Saunders BM, Orme IM, Basaraba RJ. 2008 Immunopathology of tuberculosis. In Handbook of tuberculosis: immunology and cell biology (eds SH Kaufmann, WJ Britton), pp. 245-277. Weinheim, Germany: Wiley-VCH.
48. Allen EA. 1995 Tuberculosis and other mycobacterial infections of the lung. In Pathology of the lung, 2nd edn (eds WM Thurlbeck, AM Churg), pp. 230-265. New York, NY: Thieme.
49. Chao MC, Rubin EJ. 2010 Letting sleeping dogs lie: does dormancy play a role in tuberculosis? Annu. Rev. Microbiol. 64, 293-311. (doi:10.1146/annurev. micro.112408.134043)
50. Rustad TR, Harrell MI, Liao R, Sherman DR. 2008 The enduring hypoxic response of Mycobacterium tuberculosis. PLoS ONE 3, e1502. (doi:10.1371/ journal.pone.0001502)
51. Kana BD, Mizrahi V. 2010 Resuscitation-promoting factors as lytic enzymes for bacterial growth and signaling. FEMS Immunol. Med. Microbiol. 58, 39-50. (doi:10.1111/j.1574-695X.2009.00606.x)
52. Wallgren A. 1948 The time-table of tuberculosis. Tubercle 29, 245-251. (doi:10.1016/S0041-3879(48)80033-4)
53. Poulsen A. 1950 Some clinical features of tuberculosis. 1. Incubation period. Acta Tuberc. Scand. 24, 311-346.
54. Myers JA. 1965 The natural history of tuberculosis in the human body; forty-five years of observation. JAMA 194, 1086-1092. (doi:10.1001/jama.1965. 03090230054013)
55. Poulsen A. 1957 Some clinical features of tuberculosis. Acta Tuberc. Scand. 33, 37-92.
56. Marais BJ, Gie RP, Schaaf HS, Hesseling AC, Obihara CC, Starke JJ, Enarson DA, Donald PR, Beyers N. 2004 The natural history of childhood intra-thoracic tuberculosis: a critical review of literature from the pre-chemotherapy era. Int. J. Tuberc. Lung Dis. 8, 392-402.
57. Goodwin RA, Des Prez RM. 1983 Apical localization of pulmonary tuberculosis, chronic pulmonary histoplasmosis, and progressive massive fibrosis of the lung. Chest 83, 801-805. (doi:10.1378/chest. 83.5.801)
58. Balasubramanian V, Wiegeshaus EH, Taylor BT, Smith DW. 1994 Pathogenesis of tuberculosis: pathway to apical localization. Tuberc. Lung Dis. 75, 168-178. (doi:10.1016/0962-8479(94)90002-7)
59. Rich A. 1951 The factors responsible for the characteristics of tuberculous lesions and symptoms. In The pathogenesis of tuberculosis, 2nd edn (ed. CC Thomas), pp. 704-778. Baltimore, MD: Springfield.
60. Vynnycky E, Fine PE. 1997 The natural history of tuberculosis: the implications of age-dependent risks of disease and the role of reinfection. Epidemiol. Infect. 119, 183-201. (doi:10.1017/ S0950268897007917)
61. Lillebaek T, Dirksen A, Baess I, Strunge B, Thomsen VO, Andersen AB. 2002 Molecular evidence of endogenous reactivation of Mycobacterium tuberculosis after 33 years of latent infection. J. Infect. Dis. 185, 401-404. (doi:10.1086/338342)
62. Borgdorff MW, Sebek M, Geskus RB, Kremer K, Kalisvaart N, van Soolingen D. 2011 The incubation period distribution of tuberculosis estimated with a molecular epidemiological approach. Int. J. Epidemiol. 40, 964-970. (doi:10.1093/ije/dyr058)
63. Pedrazzoli D, Anderson D, Lalor M, Davidson J, Abubakar I, Thomas L. 2013 Tuberculosis in the UK: annual report on tuberculosis surveillance in the UK. London, UK: Tuberculosis Section, Centre for Infectious Disease Surveillance and Control, Public Health England.
64. McCarthy OR. 1984 Asian immigrant tuberculosis: the effect of visiting Asia. Br. J. Dis. Chest 78, 248-253. (doi:10.1016/0007-0971(84)90136-0)
65. Wiker HG, Mustafa T, Bjune GA, Harboe M. 2010 Evidence for waning of latency in a cohort study of tuberculosis. BMC Infect. Dis. 10, 37. (doi:10.1186/ 1471-2334-10-37)
66. Steinbruck P, Dankova D, Edwards LB, Doster B, Livesay VT. 1972 Tuberculosis risk in persons with 'fibrotic' X-ray lesions. Bull. Int. Union Tuberc. 47, 135-159.
67. Vaara J, Kokkola K. 1975 Inactive pulmonary lesions: a potent risk factor of tuberculosis. Ann. Clin. Res. 7, 331-333.
68. Stead WW. 1967 Pathogenesis of the sporadic case of tuberculosis. N. Engl. J. Med. 277, 1008-1012. (doi:10.1056/NEJM196711092771906)
69. Oni T et al. 2011 High prevalence of subclinical tuberculosis in HIV-1-infected persons without advanced immunodeficiency: implications for TB screening. Thorax 66, 669-673. (doi:10.1136/thx. 2011.160168)
70. Lin PL et al. 2010 Tumor necrosis factor neutralization results in disseminated disease in acute and latent Mycobacterium tuberculosis infection with normal granuloma structure in a cynomolgus macaque model. Arthritis Rheum. 62, 340-350. (doi:10.1002/art.27271)
71. Wallis RS, Broder M, Wong J, Lee A, Hoq L. 2005 Reactivation of latent granulomatous infections by infliximab. Clin. Infect. Dis. 41(Suppl. 3), S194-S198. (doi:10.1086/429996)
72. Gomez-Reino JJ, Carmona L, Angel Descalzo M. 2007 Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection. Arthritis Rheum. 57, 756-761. (doi:10.1002/art.22768)
73. Sonnenberg P, Glynn JR, Fielding K, Murray J, Godfrey-Faussett P, Shearer S. 2005 How soon after infection with HIV does the risk of tuberculosis start to increase? A retrospective cohort study in South African gold miners. J. Infect. Dis. 191, 150-158. (doi:10.1086/426827)
74. Martinez-Pino I, Sambeat MA, Lacalle-Remigio JR, Domingo P. 2013 Incidence of tuberculosis in HIVinfected patients in Spain: the impact of treatment for LTBI. Int. J. Tuberc. Lung Dis. 17, 1545-1551. (doi:10.5588/ijtld.13.0070)
75. Elzi L, Schlegel M, Weber R, Hirschel B, Cavassini M, Schmid P, Bernasconi E, Rickenbach M, Furrer H. 2007 Reducing tuberculosis incidence by tuberculin skin testing, preventive treatment, and antiretroviral therapy in an area of low tuberculosis transmission. Clin. Infect. Dis. 44, 94-102. (doi:10.1086/510080)
76. Andrews JR, Noubary F, Walensky RP, Cerda R, Losina E, Horsburgh CR. 2012 Risk of progression to active tuberculosis following reinfection with Mycobacterium tuberculosis. Clin. Infect. Dis. 54, 784-791. (doi:10.1093/cid/cir951)
77. Sutherland I, Svandova E, Radhakrishna S. 1982 The development of clinical tuberculosis following infection with tubercle bacilli. 1. A theoretical model for the development of clinical tuberculosis following infection, linking from data on the risk of tuberculous infection and the incidence of clinical tuberculosis in the Netherlands. Tubercle 63, 255-268. (doi:10.1016/S0041-3879(82)80013-5)
78. Brooks-Pollock E, Becerra MC, Goldstein E, Cohen T, Murray MB. 2011 Epidemiologic inference from the distribution of tuberculosis cases in households in Lima, Peru. J. Infect. Dis. 203, 1582-1589. (doi:10. 1093/infdis/jir162)
79. Lurie MB. 1933 A correlation between the histological changes and the fate of living tubercle bacilli in the organs of reinfected rabbits. J. Exp. Med. 57, 181-201. (doi:10.1084/ jem.57.2.181)
80. Young DB, Gideon HP, Wilkinson RJ. 2009 Eliminating latent tuberculosis. Trends Microbiol. 17, 183-188. (doi:10.1016/j.tim.2009.02.005)
81. Barry 3rd CE, Boshoff HI, Dartois V, Dick T, Ehrt S, Flynn J, Schnappinger D, Wilkinson RJ, Young D. 2009 The spectrum of latent tuberculosis: rethinking the biology and intervention strategies. Nat. Rev. Microbiol. 7, 845-855. (doi:10.1038/ nrmicro2236)
82. Esmail H, Barry 3rd CE, Wilkinson RJ. 2012 Understanding latent tuberculosis: the key to improved diagnostic and novel treatment strategies. Drug Discov. Today 17, 514-521. (doi:10.1016/j. drudis.2011.12.013)
83. Robertson BD et al. 2012 Detection and treatment of subclinical tuberculosis. Tuberculosis 92, 447-452. (doi:10.1016/j.tube.2012.06.004)
84. Lin PL, Flynn JL. 2010 Understanding latent tuberculosis: a moving target. J. Immunol. 185, 15-22. (doi:10.4049/jimmunol.0903856)
85. Tobin DM et al. 2010 The lta4h locus modulates susceptibility to mycobacterial infection in zebrafish and humans. Cell 140, 717-730. (doi:10.1016/j. cell.2010.02.013)
86. Tobin DM et al. 2012 Host genotype-specific therapies can optimize the inflammatory response to mycobacterial infections. Cell 148, 434-446. (doi:10.1016/j.cell.2011.12.023)
87. Lalvani A, Behr MA, Sridhar S. 2012 Innate immunity to TB: a druggable balancing act. Cell 148, 389-391. (doi:10.1016/j.cell.2012.01.026)
88. Donald PR, Marais BJ, Barry 3rd CE. 2010 Age and the epidemiology and pathogenesis of tuberculosis. Lancet 375, 1852-1854. (doi:10.1016/S0140-6736(10)60580-6)
89. Hernandez-Pando R, de la Luz Streber M, Orozco H, Arriaga K, Pavon L, Marti O, Lightman SL, Rook GA. 1998 Emergent immunoregulatory properties of combined glucocorticoid and anti-glucocorticoid steroids in a model of tuberculosis. QJM 91, 755-766. (doi:10.1093/qjmed/91.11.755)
90. Angerami M, Suarez G, Pascutti MF, Salomon H, Bottasso O, Quiroga MF. 2013 Modulation of the phenotype and function of Mycobacterium tuberculosis-stimulated dendritic cells by adrenal steroids. Int. Immunol. 25, 405-411. (doi:10.1093/ intimm/dxt004)
91. Naranbhai V, Hill AV, Abdool Karim SS, Naidoo K, Abdool Karim Q, Warimwe GM, McShane H, Fletcher H. 2013 Ratio of monocytes to lymphocytes in peripheral blood identifies adults at risk of incident tuberculosis among HIV-infected adults initiating antiretroviral therapy. J. Infect. Dis. 209, 500-509. (doi:10.1093/infdis/jit494)
92. Coussens AK et al. 2012 Vitamin D accelerates resolution of inflammatory responses during tuberculosis treatment. Proc. Natl Acad. Sci. USA 109, 15 449-15 454. (doi:10.1073/pnas. 1200072109)
93. Fares A. 2011 Seasonality of tuberculosis. J. Glob. Infect. Dis. 3, 46-55. (doi:10.4103/0974-777X.77296)
94. Koh GC, Hawthorne G, Turner AM, Kunst H, Dedicoat M. 2013 Tuberculosis incidence correlates with sunshine: an ecological 28-year time series study. PLoS ONE 8, e57752. (doi:10.1371/journal.pone. 0057752)
95. Willis MD, Winston CA, Heilig CM, Cain KP, Walter ND, Mac Kenzie WR. 2012 Seasonality of tuberculosis in the United States, 1993-2008. Clin. Infect. Dis. 54, 1553-1560. (doi:10.1093/ cid/cis235)
96. Maclachlan JH, Lavender CJ, Cowie BC. 2012 Effect of latitude on seasonality of tuberculosis, Australia, 2002-2011. Emerg. Infect. Dis. 18, 1879-1881. (doi:10.3201/eid1811.120456)
97. Soetens LC, Boshuizen HC, Korthals Altes H. 2013 Contribution of seasonality in transmission of Mycobacterium tuberculosis to seasonality in tuberculosis disease: a simulation study. Am. J. Epidemiol. 178, 1281-1288. (doi:10.1093/aje/kwt114)
98. Top R, Boshuizen H, Dekkers A, Korthals Altes H. 2013 Similar seasonal peak in clustered and unique extra-pulmonary tuberculosis notifications: winter crowding hypothesis ruled out? Int. J. Tuberc. Lung Dis. 17, 1466-1471. (doi:10.5588/ijtld.13.0226)
99. Martineau AR. 2012 Old wine in new bottles: vitamin D in the treatment and prevention of tuberculosis. Proc. Nutr. Soc. 71, 84-89. (doi:10. 1017/S0029665111003326)
100. Nnoaham KE, Clarke A. 2008 Low serum vitamin D levels and tuberculosis: a systematic review and meta-analysis. Int. J. Epidemiol. 37, 113-119. (doi:10.1093/ije/dym247)
101. Wilkinson RJ, Llewelyn M, Toossi Z, Patel P, Pasvol G, Lalvani A, Wright D, Latif M, Davidson RN. 2000 Influence of vitamin D deficiency and vitamin D receptor polymorphisms on tuberculosis among Gujarati Asians in west London: a case-control study. Lancet 355, 618-621. (doi:10.1016/S0140-6736(99)02301-6)
102. Martineau AR et al. 2011 Reciprocal seasonal variation in vitamin D status and tuberculosis notifications in Cape Town, South Africa. Proc. Natl Acad. Sci. USA 108, 19 013-19 017. (doi:10.1073/ pnas.1111825108)
103. Korthals Altes H, Kremer K, Erkens C, van Soolingen D, Wallinga J. 2012 Tuberculosis seasonality in the Netherlands differs between natives and non-natives: a role for vitamin D deficiency? Int. J. Tuberc. Lung Dis. 16, 639-644. (doi:10.5588/ijtld.11.0680)
104. Douglas AS, Ali S, Bakhshi SS. 1998 Does vitamin D deficiency account for ethnic differences in tuberculosis seasonality in the UK? Ethn. Health 3, 247-253. (doi:10.1080/13557858.1998.9961867)
105. Teles RM et al. 2013 Type I interferon suppresses type II interferon-triggered human antimycobacterial responses. Science 339, 1448-1453. (doi:10.1126/science.1233665)
106. Redford PS, Mayer-Barber KD, McNab FW, Stavropoulos E, Wack A, Sher A, O'Garra A. 2013 Influenza A virus impairs control of Mycobacterium tuberculosis coinfection through a type i interferon receptor-dependent pathway. J. Infect. Dis. 209, 270-274. (doi:10.1093/infdis/jit424)
107. Oei W, Nishiura H. 2012 The relationship between tuberculosis and influenza death during the influenza (H1N1) pandemic from 1918-19. Comput. Math. Methods Med. 2012, 124861. (doi:10.1155/2012/124861)
108. Osorio NS, Rodrigues F, Gagneux S, Pedrosa J, Pinto-Carbo M, Castro AG, Young D, Comas I, Saraiva M. 2013 Evidence for diversifying selection in a set of Mycobacterium tuberculosis genes in response to antibiotic-and nonantibiotic-related pressure. Mol. Biol. Evol. 30, 1326-1336. (doi:10.1093/molbev/ mst038)
109. van Zyl-Smit RN, Zwerling A, Dheda K, Pai M. 2009 Within-subject variability of interferon-g assay results for tuberculosis and boosting effect of tuberculin skin testing: a systematic review. PLoS ONE 4, e8517. (doi:10.1371/journal. pone.0008517)
110. Metcalfe JZ, Everett CK, Steingart KR, Cattamanchi A, Huang L, Hopewell PC, Pai M. 2011 Interferon-gamma release assays for active pulmonary tuberculosis diagnosis in adults in low-and middle-income countries: systematic review and meta-analysis. J. Infect. Dis. 204(Suppl. 4), S1120-S1129. (doi:10. 1093/infdis/jir410)
111. Pai M, Zwerling A, Menzies D. 2008 Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann. Intern. Med. 149, 177-184. (doi:10.7326/0003-4819-149-3-200808050-00241)
112. Menzies D, Pai M, Comstock G. 2007 Meta-analysis: new tests for the diagnosis of latent tuberculosis infection: areas of uncertainty and recommendations for research. Ann. Intern. Med. 146, 340-354. (doi:10.7326/0003-4819-146-5-200703060-00006)
113. Berry MP et al. 2010 An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature 466, 973-977. (doi:10. 1038/nature09247)
114. Kaforou M et al. 2013 Detection of tuberculosis in HIV-infected and-uninfected African adults using whole blood RNA expression signatures: a casecontrol study. PLoS Med. 10, e1001538. (doi:10. 1371/journal.pmed.1001538)
115. Fox W, Ellard GA, Mitchison DA. 1999 Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications. Int. J. Tuberc. Lung Dis. 3, S231-S279.
116. Comstock GW. 1999 How much isoniazid is needed for prevention of tuberculosis among immunocompetent adults? Int. J. Tuberc. Lung Dis. 3, 847-850.
117. Sharma SK, Sharma A, Kadhiravan T, Tharyan P. 2013 Rifamycins (rifampicin, rifabutin and rifapentine) compared to isoniazid for preventing tuberculosis in HIV-negative people at risk of active TB. Cochrane Database Syst. Rev. 7, CD007545. (doi:10.1002/14651858.CD007545.pub2)
118. Grosset JH, Singer TG, Bishai WR. 2012 New drugs for the treatment of tuberculosis: hope and reality. Int. J. Tuberc. Lung Dis. 16, 1005-1014. (doi:10. 5588/ijtld.12.0277)
119. Williams K, Minkowski A, Amoabeng O, Peloquin CA, Taylor D, Andries K, Wallis RS, Mdluli KE, Nuermberger EL. 2012 Sterilizing activities of novel combinations lacking first-and second-line drugs in a murine model of tuberculosis. Antimicrob. Agents Chemother. 56, 3114-3120. (doi:10.1128/AAC. 00384-12)
120. Shepardson D et al. 2013 Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States. Int. J. Tuberc. Lung Dis. 17, 1531-1537. (doi:10.5588/ijtld.13.0423)
121. Kaim AH, Weber B, Kurrer MO, Gottschalk J, Von Schulthess GK, Buck A. 2002 Autoradiographic quantification of 18F-FDG uptake in experimental soft-tissue abscesses in rats. Radiology 223, 446-451. (doi:10.1148/radiol.2232010914)
122. Treglia G, Taralli S, Calcagni ML, Maggi F, Giordano A, Bonomo L. 2011 Is there a role for fluorine 18 fluorodeoxyglucose-positron emission tomography and positron emission tomography/computed tomography in evaluating patients with mycobacteriosis? A systematic review. J. Comput. Assist. Tomogr. 35, 387-393. (doi:10.1097/RCT. 0b013e318219f810)
123. Kim IJ, Lee JS, Kim SJ, Kim YK, Jeong YJ, Jun S, Nam HY, Kim JS. 2008 Double-phase 18F-FDG PETCT for determination of pulmonary tuberculoma activity. Eur. J. Nucl. Med. Mol. Imaging 35, 808-814. (doi:10.1007/s00259-007-0585-0)
124. Goo JM, Im JG, Do KH, Yeo JS, Seo JB, Kim HY, Chung JK. 2000 Pulmonary tuberculoma evaluated by means of FDG PET: findings in 10 cases. Radiology 216, 117-121. (doi:10.1148/radiology. 216.1.r00jl19117)
125. Sathekge M, Maes A, Kgomo M, Stoltz A, Van de Wiele C. 2011 Use of 18F-FDG PET to predict response to first-line tuberculostatics in HIVassociated tuberculosis. J. Nucl. Med. 52, 880-885. (doi:10.2967/jnumed.110.083709)
126. Aagaard C et al. 2011 A multistage tuberculosis vaccine that confers efficient protection before and after exposure. Nat. Med. 17, 189-194. (doi:10. 1038/nm.2285)
127. Tameris MD et al. 2013 Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial. Lancet 381, 1021-1028. (doi:10.1016/S0140-6736(13) 60177-4)
128. Bishai W, Sullivan Z, Bloom BR, Andersen P. 2013 Bettering BCG: a tough task for a TB vaccine? Nat. Med. 19, 410-411. (doi:10.1038/nm.3153)
129. Vilaplana C, Montane E, Pinto S, Barriocanal AM, Domenech G, Torres F, Cardona PJ, Costa J. 2010 Double-blind, randomized, placebo-controlled phase I clinical trial of the therapeutical antituberculous vaccine RUTI. Vaccine 28, 1106-1116. (doi:10. 1016/j.vaccine.2009.09.134)